NCT01435395View on ClinicalTrials.gov

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Glioblastoma Multiforme
Interventions
DRUG

Temozolomide, bevacizumab and bortezomib

Escalating temozolomide with standard dose bevacizumab and bortezomib

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Emory University

OTHER

NCT01435395 - Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter